Genitsch, Vera; Kollár, Attila; Vandekerkhove, Gillian; Blarer, Jennifer; Furrer, Marc; Annala, Matti; Herberts, Cameron; Pycha, Armin; de Jong, Joep J; Liu, Yang; Krentel, Friedemann; Davicioni, Elai; Wyatt, Alexander W; Gibb, Ewan A; Kruithof-de Julio, Marianna; Seiler, Roland (2019). Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic oncology - seminars and original investigations, 37(11), pp. 826-836. Elsevier 10.1016/j.urolonc.2019.09.025
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S107814391930376X-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (3MB) | Request a copy |
INTRODUCTION
The sarcomatoid morphology of muscle-invasive bladder cancer (MIBC) is associated with unfavorable prognosis. However, the genomic, transcriptomic, and proteomic relationship between conventional urothelial and synchronous sarcomatoid morphology is poorly defined.
METHODS
We compiled a cohort of 21 MIBC patients with components of conventional urothelial and adjacent sarcomatoid morphology within the same tumor focus. We performed comprehensive pathologic and immunohistochemical characterization and in 4 selected cases, subjected both morphologic components to targeted DNA sequencing and whole transcriptome analysis.
RESULTS
Synchronous sarcomatoid and urothelial morphology from the same MIBC foci shared truncal somatic mutations, indicating a common ancestral clone. However, additional mutations or copy number alterations restricted to the either component suggested divergent evolution at the genomic level. This was confirmed at the transcriptome level since while the urothelial component exhibited a basal-like subtype (TCGA2014: cluster III, LundTax: basal/squamous-like), the sarcomatoid morphology was predominantly cluster IV (claudin-low). Protein expression was consistent with a basal-like phenotype in both morphologies in 18/21 of cases. However, most cases had evidence of active epithelial-to-mesenchymal transition (E-Cad ↓ and Zeb1 or TWIST1 ↑) from urothelial toward the sarcomatoid morphology. Drug response signatures nominated different targets for each morphology and proposed agents under clinical investigation in liposarcoma or other sarcoma. PD-L1 expression was higher in the sarcomatoid than the urothelial component.
CONCLUSIONS
Conventional urothelial and adjacent sarcomatoid morphologies of MIBC arise from the same common ancestor and share a basal-like phenotype. However, divergence between the morphologies at the genome, transcriptome, and proteome level suggests differential sensitivity to therapy.
Actions (login required)
 |
Edit item |